Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMTE8DC)

Drug Name
Pozelimab Drug Info
Synonyms REGN3918
Indication
Disease Entry ICD 11 Status REF
Approved [1]
Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DMTE8DC

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement C5 (CO5) TTKANGO CO5_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease
ICD Disease Classification
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Complement C5 (CO5) DTT C5 7.69E-01 -0.12 -0.23
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761339
2 ClinicalTrials.gov (NCT04888507) Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy. U.S. National Institutes of Health.
3 Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5. PLoS One. 2020 May 8;15(5):e0231892.